Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,138.80
(
-0.49%
)
US TECH 100
26,328.40
(
-0.91%
)
Dow Jones
49,141.93
(
-0.34%
)
Brent Oil
104.27
(
2.11%
)
Bitcoin
76,455.16
(
-1.18%
)
News Focus
News Focus
Post# of 257458
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Mufaso

Send PM Follow Ignore
Followers 42
Posts 697
Boards Moderated 0
Alias Born 01/08/2008

Mufaso

Re: DewDiligence post# 254803

Wednesday, 03/12/2025 5:26:57 PM

Wednesday, March 12, 2025 5:26:57 PM

Post# of 257458
Dew- Did you see the abstract conclusion on that paper?

Conclusion
Immunogenicity did not affect TZP pharmacokinetics or efficacy. The majority of hypersensitivity or injection site reactions experienced by TE ADA+ patients were mild to moderate in severity.


https://academic.oup.com/jcem/article/109/2/361/7272290

What is your take on the significance of >50% of pts develop ADA against Tirzepatide? Also - What is your take on the significance "2% has neutralizing Ab against TZP activity at GIPr & GLP1r" or any other conclusions you draw from this paper? TIA

"People are best convinced by reasons they discover themselves"

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today